Ipilimumab is a novel humanized monoclonal antibody directed against cytotoxic T lymphocyte antigen 4, a T-cell surface molecule involved in down-regulation and suppression of the T cell response to stimuli. Patients treated with ipilimumab are at risk for immune-related adverse events involving the skin, digestive tract, liver and endocrine organs. Few case reports of immune-related adverse effects involving central or peripheral nervous system due to ipilimumab are published. These include inflammatory myopathy, aseptic meningitis, severe meningo-radiculo-neuritis, temporal arteritis, Guillain-Barre syndrome, and posterior reversible encephalopathy syndrome. We report the first case of ipilimumab-induced progressive necrotic myelopathy.
PardollDM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer2012; 12: 252–264.
2.
PeggsKSQuezadaSAKormanAJ. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol2006; 18: 206–213.
3.
HodiFSO’DaySJMcDermottDF. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med2010; 363: 711–723.
4.
WolchokJDNeynsBLinetteG. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol2009; 11: 155–164.
5.
WeberJ. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother2009; 58: 823–830.
6.
IbrahimRBermanDde PrilV. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol2011; 29. abstract no. 8583.
7.
HunterGVollCRobinsonCA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Canadian J Neurol Sci2009; 36: 518–520.
8.
YangJCHughesMKammulaU. Ipilimumab (anti- CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother2007; 30: 825–830.
9.
BompaireFMateusCTailliaH. Severe meningoradiculo-nevritis associated with ipilimumab. Investig New Drugs2012; 30: 2407–2410.
10.
KornELLiuPYLeeSJ. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol2008; 26: 527–534.
11.
WilgenhofSNeynsB. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol2011; 22: 991–993.
12.
MaurMTomaselloCFrassoldatiA. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol2012; 30: e76–8.
Yervoy (ipilimumab) Injection, prescribing information. Princeton, NJ: Bristol- Myers Squibb; March 2011, http://packageinserts.bms.com (accessed 18 January 2012).
21.
PatelSPWoodmanSE. Profile of ipilimumab and its role in treatment of metastatic melanoma. Drug Des Devel Ther2011; 5: 489–495.
22.
AndrewsSHoldenR. Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res2012; 4: 299–307.
23.
LeachBCKulbershJSDayTA. Cranial neuropathy as a presenting sign of recurrent aggressive skin cancer. Dermatol Surg2008; 34: 483–497.
24.
PainterTJChaljubGSethiR. Intracranial and intraspinal meningeal melanocytosis. AJNR Am J Neuroradiol2000; 21: 1349–1353.
25.
ManousakisGKochJSommervilleB. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve2013; 48: 440–444.
26.
TarhiniALoEMinorDR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm2010; 25: 601–613.
27.
Von EuwEChodonTAttarN. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med2009; 7: 35–35.
28.
BettelliEOukkaMKuchrooVK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol2007; 8(4): 345–350.
29.
Callahan MK, Yang A, Tandon S, et al. Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. In: ASCO meeting abstracts 2505, 2011.
30.
ClementeCGMihmMCJrBufalinoR. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer1996; 77: 1303–1310.
31.
AttiaPPhanGQMakerAV. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic Tlymphocyte antigen-4. J Clin Oncol2005; 23: 6043–6053.
32.
LemechCArkenauHT. Novel treatments formetastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights, Oncol2012; 6: 53–66.
33.
WeberJSKählerKCHauschildA. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol2012; 30: 2691–2697.
34.
JohnstonRLLutzkyJChodhryA. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci2009; 54: 2538–2540.
